Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,080 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group.
Eigentler TK, Radny P, Hauschild A, Gutzmer R, Linse R, Pföhler C, Wagner SN, Schadendorf D, Ellwanger U, Garbe C; German Dermatologic Cooperative Oncology Group. Eigentler TK, et al. Among authors: schadendorf d. Melanoma Res. 2008 Oct;18(5):353-8. doi: 10.1097/CMR.0b013e32830e3936. Melanoma Res. 2008. PMID: 18781134 Clinical Trial.
Skin cancers are the most frequent cancers in fair-skinned populations, but we can prevent them.
Garbe C, Forsea AM, Amaral T, Arenberger P, Autier P, Berwick M, Boonen B, Bylaite M, Del Marmol V, Dreno B, Fargnoli MC, Geller AC, Green AC, Greinert R, Hauschild A, Harwood CA, Hoorens I, Kandolf L, Kaufmann R, Kelleners-Smeets N, Lallas A, Lebbé C, Leiter U, Lim HW, Longo C, Malvehy J, Moreno D, Pellacani G, Peris K, Robert C, Saiag P, Schadendorf D, Peter Soyer H, Stockfleth E, Stratigos A, Uhara H, Vieira R, Volkmer B, Weinstock MA, Whitaker D, Zalaudek I, Whiteman DC, Brochez L. Garbe C, et al. Among authors: schadendorf d. Eur J Cancer. 2024 Jun;204:114074. doi: 10.1016/j.ejca.2024.114074. Epub 2024 Apr 24. Eur J Cancer. 2024. PMID: 38691877 Free article. Review.
Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma.
Long GV, Stephen Hodi F, Lipson EJ, Schadendorf D, Ascierto PA, Matamala L, Salman P, Castillo Gutiérrez E, Rutkowski P, Gogas HJ, Lao CD, Janoski De Menezes J, Dalle S, Arance A, Grob JJ, Keidel S, Shaikh A, Sobiesk AM, Dolfi S, Tawbi HA. Long GV, et al. Among authors: schadendorf d. NEJM Evid. 2023 Apr;2(4):EVIDoa2200239. doi: 10.1056/EVIDoa2200239. Epub 2023 Mar 22. NEJM Evid. 2023. PMID: 38320023 Clinical Trial.
Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A; KEYNOTE-006 investigators. Robert C, et al. N Engl J Med. 2015 Jun 25;372(26):2521-32. doi: 10.1056/NEJMoa1503093. Epub 2015 Apr 19. N Engl J Med. 2015. PMID: 25891173 Free article. Clinical Trial.
Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
Kennedy OJ, Glassee N, Kicinski M, Blank CU, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Boers-Sonderen M, Giacomo AMD, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Gandini S, Buhrer E, Suciu S, Robert C, Eggermont AMM, Mandala M, Lorigan P, Valpione S. Kennedy OJ, et al. Among authors: schadendorf d. Eur J Cancer. 2024 Apr;201:113585. doi: 10.1016/j.ejca.2024.113585. Epub 2024 Feb 1. Eur J Cancer. 2024. PMID: 38402687 Clinical Trial.
One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis.
Reich K, Puig L, Paul C, Kragballe K, Luger T, Lambert J, Chimenti S, Girolomoni G, Nicolas JF, Rizova E, Brunori M, Mistry S, Bergmans P, Barker J; TRANSIT Investigators. Reich K, et al. Br J Dermatol. 2014 Feb;170(2):435-44. doi: 10.1111/bjd.12643. Br J Dermatol. 2014. PMID: 24116868 Clinical Trial.
Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT).
Paul C, Puig L, Kragballe K, Luger T, Lambert J, Chimenti S, Girolomoni G, Nicolas JF, Rizova E, Lavie F, Mistry S, Bergmans P, Barker J, Reich K; TRANSIT Investigators. Paul C, et al. Br J Dermatol. 2014 Feb;170(2):425-34. doi: 10.1111/bjd.12646. Br J Dermatol. 2014. PMID: 24116959 Free article. Clinical Trial.
Secukinumab in plaque psoriasis--results of two phase 3 trials.
Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C; ERASURE Study Group; FIXTURE Study Group. Langley RG, et al. N Engl J Med. 2014 Jul 24;371(4):326-38. doi: 10.1056/NEJMoa1314258. Epub 2014 Jul 9. N Engl J Med. 2014. PMID: 25007392 Free article. Clinical Trial.
Loss of p14 diminishes immunogenicity in melanoma via non-canonical Wnt signaling by reducing the peptide surface density.
Wohlfarth J, Kosnopfel C, Faber D, Berthold M, Siedel C, Bernhardt M, Schlosser A, Aprati T, Liu D, Schrama D, Houben R, Schadendorf D, Goebeler M, Meierjohann S, Schilling B. Wohlfarth J, et al. Among authors: schadendorf d. Mol Oncol. 2024 May 28. doi: 10.1002/1878-0261.13660. Online ahead of print. Mol Oncol. 2024. PMID: 38807304
1,080 results